Literature DB >> 18591277

In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.

Karen M Amsler1, Todd A Davies, Wenchi Shang, Michael R Jacobs, Karen Bush.   

Abstract

In phase 3 clinical trials for ceftobiprole treatment of complicated skin and skin structure infections, 1,219 gram-positive and 276 gram-negative aerobic baseline pathogens were identified. Ceftobiprole inhibited all staphylococcal isolates, including methicillin-resistant strains, at MICs of </=4 mug/ml. Against Enterobacteriaceae and Pseudomonas aeruginosa isolates, the potency of ceftobiprole was similar to that of cefepime.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18591277      PMCID： PMC2533453          DOI： 10.1128/AAC.00336-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

Review 1.  Complicated infections of skin and skin structures: when the infection is more than skin deep.

Authors:  Mark J DiNubile; Benjamin A Lipsky
Journal:  J Antimicrob Chemother       Date:  2004-06       Impact factor: 5.790

Review 2.  Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance.

Authors:  Su Young Lee; Joseph L Kuti; David P Nicolau
Journal:  Surg Infect (Larchmt)       Date:  2005       Impact factor: 2.150

3.  In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections.

Authors:  Patricia A Bradford; D Tasha Weaver-Sands; Peter J Petersen
Journal:  Clin Infect Dis       Date:  2005-09-01       Impact factor: 9.079

4.  Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin.

Authors:  Tatiana Bogdanovich; Lois M Ednie; Stuart Shapiro; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

Review 5.  Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy.

Authors:  Karen Bush; Markus Heep; Mark J Macielag; Gary J Noel
Journal:  Expert Opin Investig Drugs       Date:  2007-04       Impact factor: 6.206

6.  Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).

Authors:  Gary J Moet; Ronald N Jones; Douglas J Biedenbach; Matthew G Stilwell; Thomas R Fritsche
Journal:  Diagn Microbiol Infect Dis       Date:  2006-10-23       Impact factor: 2.803

7.  Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections.

Authors:  John Weigelt; Kamal Itani; Dennis Stevens; William Lau; Matthew Dryden; Charles Knirsch
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

8.  Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections.

Authors:  Luis E Jauregui; Simon Babazadeh; Elyse Seltzer; Lisa Goldberg; Dainis Krievins; Mark Frederick; David Krause; Igors Satilovs; Zilvinas Endzinas; Jeffrey Breaux; William O'Riordan
Journal:  Clin Infect Dis       Date:  2005-10-06       Impact factor: 9.079

9.  Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate.

Authors:  Benjamin A Lipsky; Philip Giordano; Shurjeel Choudhri; James Song
Journal:  J Antimicrob Chemother       Date:  2007-06-06       Impact factor: 5.790

10.  A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections.

Authors:  Gary J Noel; Karen Bush; Partha Bagchi; Juliana Ianus; Richard S Strauss
Journal:  Clin Infect Dis       Date:  2008-03-01       Impact factor: 9.079
View more
  9 in total

1.  Epidemiology of invasive neonatal Cronobacter (Enterobacter sakazakii) infections.

Authors:  M Friedemann
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-08-07       Impact factor: 3.267

2.  Population pharmacokinetic analysis of ceftobiprole for treatment of complicated skin and skin structure infections.

Authors:  Holly Kimko; Bindu Murthy; Xu Xu; Partha Nandy; Richard Strauss; Gary J Noel
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

Review 3.  Newer antibacterial drugs for a new century.

Authors:  Gina Devasahayam; William M Scheld; Paul S Hoffman
Journal:  Expert Opin Investig Drugs       Date:  2010-02       Impact factor: 6.206

4.  Activities of ceftobiprole and other cephalosporins against extracellular and intracellular (THP-1 macrophages and keratinocytes) forms of methicillin-susceptible and methicillin-resistant Staphylococcus aureus.

Authors:  Sandrine Lemaire; Youri Glupczynski; Valérie Duval; Bernard Joris; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2009-03-16       Impact factor: 5.191

5.  In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.

Authors:  Jeffrey Fernandez; Jamese J Hilliard; Darren Abbanat; Wenyan Zhang; John L Melton; Colleen M Santoro; Robert K Flamm; Karen Bush
Journal:  Antimicrob Agents Chemother       Date:  2009-11-02       Impact factor: 5.191

6.  A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia.

Authors:  Samir S Awad; Alejandro H Rodriguez; Yin-Ching Chuang; Zsuszanna Marjanek; Alex J Pareigis; Gilmar Reis; Thomas W L Scheeren; Alejandro S Sánchez; Xin Zhou; Mikaël Saulay; Marc Engelhardt
Journal:  Clin Infect Dis       Date:  2014-04-09       Impact factor: 9.079

7.  Resistance and the management of complicated skin and skin structure infections: the role of ceftobiprole.

Authors:  April Barbour; Hartmut Derendorf
Journal:  Ther Clin Risk Manag       Date:  2010-10-05       Impact factor: 2.423

8.  Ceftobiprole Compared With Vancomycin Plus Aztreonam in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Results of a Phase 3, Randomized, Double-blind Trial (TARGET).

Authors:  J Scott Overcash; Charles Kim; Richard Keech; Illia Gumenchuk; Borislav Ninov; Yaneicy Gonzalez-Rojas; Michael Waters; Simeon Simeonov; Marc Engelhardt; Mikael Saulay; Daniel Ionescu; Jennifer I Smart; Mark E Jones; Kamal A Hamed
Journal:  Clin Infect Dis       Date:  2021-10-05       Impact factor: 9.079

9.  Antioxidant and Antimicrobial Potentials of Seed Oil from Carthamus tinctorius L. in the Management of Skin Injuries.

Authors:  Ikram Khémiri; Badiaa Essghaier; Najla Sadfi-Zouaoui; Lotfi Bitri
Journal:  Oxid Med Cell Longev       Date:  2020-11-04       Impact factor: 6.543
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.